Search results
Results from the WOW.Com Content Network
Tegafur/gimeracil/oteracil, sold under the brand name Teysuno among others is a fixed-dose combination medication used for the treatment of advanced gastric cancer when used in combination with cisplatin, [3] and also for the treatment of head and neck cancer, colorectal cancer, non–small-cell lung, breast, pancreatic, and biliary tract cancers.
The proton pump is the terminal stage in gastric acid secretion, being directly responsible for secreting H + ions into the gastric lumen, making it an ideal target for inhibiting acid secretion. [ citation needed ] Because the H,K-ATPase is the final step of acid secretion, an inhibitor of this enzyme is more effective than receptor ...
Stomach cancer, also known as gastric cancer, is a malignant tumor of the stomach. It's a cancer that develops from the lining of the stomach . [ 10 ] Most cases of stomach cancers are gastric carcinomas , which can be divided into a number of subtypes, including gastric adenocarcinomas . [ 2 ]
A new opioid-free pain medication was approved by the U.S. Food and Drug Administration (FDA) on Thursday, marking a non-addictive alternative for patients. Journavx (suzetrigine), made by Vertex ...
Gastric lipase is synthesized and secreted from gastric chief cells in the stomach and is stable at pH 1,5-8, [21] but has maximum activity at pH 3-6. [20] Fat digestion begins when gastric lipase hydrolyses dietary triglycerides, by cleaving only one long-, medium- or short- acyl chain from the glyceride backbone and release free fatty acids ...
Gastrointestinal cancer refers to malignant conditions of the gastrointestinal tract (GI tract) and accessory organs of digestion, including the esophagus, stomach, biliary system, pancreas, small intestine, large intestine, rectum and anus. The symptoms relate to the organ affected and can include obstruction (leading to difficulty swallowing ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Imatinib was approved for metastatic and unresectable GIST by the U.S. FDA on February 1, 2002. The two-year survival of patients with advanced disease has risen to 75–80% following imatinib treatment. [39] If resistance to imatinib is encountered, the multiple-tyrosine-kinase inhibitor sunitinib (marketed as Sutent) can be considered.